NinePointTwo Capital’s Castle Biosciences CSTL Stock Holding History

NinePointTwo Capital’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-6,965	Closed	-$312K	–	211
2022 Q1	$312K	Hold	6,965	–	–	0.08%	108
2021 Q4	$298K	Buy	+6,965	New	+$364K	0.1%	64
2021 Q3	–	Sell	-2,819	Closed	-$206K	–	86
2021 Q2	$206K	Buy	+2,819	New	+$186K	0.07%	60

Other funds holding CSTL

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

KCM

Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

NinePointTwo Capital's CSTL Position: Q2 2022 in Review

NinePointTwo Capital sold out of Castle Biosciences (CSTL) in Q2 2022, closing a stake of 6,965 shares — an estimated $312K sold.

NinePointTwo Capital first reported a position in CSTL in Q2 2021 and held it in 3 quarters. The position peaked at $312K in Q1 2022. 146 funds tracked by Wall St. Rank hold CSTL as of Q2 2022.

NinePointTwo Capital reported no remaining Castle Biosciences position as of Q2 2022 after selling out during the quarter.
NinePointTwo Capital sold 6,965 Castle Biosciences shares in Q2 2022, an estimated $312K.
NinePointTwo Capital first reported a position in Castle Biosciences in Q2 2021 and held it in 3 quarters.
NinePointTwo Capital's Castle Biosciences position peaked at $312K in Q1 2022.
146 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2022.

Based on NinePointTwo Capital's 13F filing for Q2 2022, filed 15 Aug 2022.